Old College Capital (OCC)
Partners
Old College Capital (OCC)
Old College Capital (OCC) is the University of Edinburgh’s venture investment fund. They manage Edinburgh’s early-stage investment activities and shareholdings; supporting exciting ideas and technologies emerging from the University. OCC is part of Edinburgh Innovations, the University of Edinburgh’s commercialisation service.
The Fund aims to support the University’s research, staff and students by investing in high-growth, early-stage businesses associated with the University and follows a co-investment model by partnering with experienced private sector investors. Working closely with founders, investors, and the University ecosystem, Old College Capital accelerates the journey of start-ups and spinouts that are looking to make a positive impact on people and our planet. Committed to investing for the long term, OCC reinvests its returns so that it can support the next generation of early-stage companies.
Concinnity Genetics
Gene therapies are revolutionising disease treatment with the potential to cure previously untreatable illnesses. However, the complete realisation of their potential is being hindered by safety concerns. Gene therapies are thus constrained to severe rare diseases where risk tolerance for therapy is high. Addressing safety issues will be crucial to unlocking their full therapeutic benefits and ensuring their safe and widespread adoption in clinical practice.
Concinnity is transforming the safety of gene therapies by designing novel control mechanisms using its innovative AI platform and synthetic biology expertise. These unique RNA-based systems enable the precise control of gene therapies even after dosing, with the ability to respond to and reduce their own side effects.
We aim to become the go-to partner for gene control in cell and gene therapy, empowering our visionary partners to design and optimise their gene therapies in the confidence that they will be making them as safe as possible.
Neuranics
Our magnetocardiography (MCG) sensors have a single point of contact on the body, or through thin clothing, which will replace existing 3-lead electrocardiography (ECG) sensors for use in sports fitness devices and medical monitoring devices. The MCG signal gives greater resolution and clarity on the operation of the heart and can show blood movement within the main heart valves.